Xin Lang Cai Jing·2026-02-03 07:45Core Viewpoint - The company, BeiGene, is a leading global innovator in cancer treatment, focusing on developing innovative anti-tumor drugs to enhance accessibility and affordability for cancer patients [2]. Financial Performance - For the period from January to September 2025, BeiGene achieved a revenue of 27.595 billion yuan, representing a year-on-year growth of 44.21% [6]. - The net profit attributable to the parent company was 1.139 billion yuan, showing a significant year-on-year increase of 130.88% [6]. Market Activity - On February 3, BeiGene's stock rose by 1.64%, with a trading volume of 651 million yuan and a turnover rate of 2.08%, bringing the total market capitalization to 421.221 billion yuan [1]. - The stock has seen a net outflow of 17.2595 million yuan from major investors today, with a ranking of 145 out of 158 in the industry [3][4]. Shareholder Information - As of September 30, 2025, the number of shareholders for BeiGene increased to 36,200, a rise of 55.33% compared to the previous period [6]. - The average number of tradable shares per shareholder decreased by 35.79% to 3,195 shares [6]. Institutional Holdings - Among the top ten circulating shareholders, China Europe Medical Health Mixed A holds 4.6788 million shares, a decrease of 146,600 shares from the previous period [7]. - Hong Kong Central Clearing Limited is a new shareholder with 3.1565 million shares [7].